$8.74
1.52% today
Nasdaq, Apr 01, 06:45 pm CET
ISIN
US62855J1043
Symbol
MYGN

Myriad Genetics, Inc. Stock price

$8.87
-1.86 17.33% 1M
-18.52 67.62% 6M
-4.84 35.30% YTD
-12.57 58.63% 1Y
-16.33 64.80% 3Y
-5.44 38.02% 5Y
-26.53 74.94% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.01 0.11%
ISIN
US62855J1043
Symbol
MYGN
Sector
Industry

Key metrics

Market capitalization $809.91m
Enterprise Value $839.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.00
P/S ratio (TTM) P/S ratio 0.97
P/B ratio (TTM) P/B ratio 1.16
Revenue growth (TTM) Revenue growth 11.21%
Revenue (TTM) Revenue $837.60m
EBIT (operating result TTM) EBIT $-89.20m
Free Cash Flow (TTM) Free Cash Flow $-27.70m
Cash position $111.00m
EPS (TTM) EPS $-1.40
P/E forward negative
P/S forward 0.96
EV/Sales forward 0.99
Short interest 7.79%
Show more

Is Myriad Genetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Myriad Genetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Myriad Genetics, Inc. forecast:

8x Buy
47%
5x Hold
29%
4x Sell
24%

Analyst Opinions

17 Analysts have issued a Myriad Genetics, Inc. forecast:

Buy
47%
Hold
29%
Sell
24%

Financial data from Myriad Genetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
838 838
11% 11%
100%
- Direct Costs 284 284
2% 2%
34%
554 554
17% 17%
66%
- Selling and Administrative Expenses 472 472
2% 2%
56%
- Research and Development Expense 110 110
24% 24%
13%
-28 -28
62% 62%
-3%
- Depreciation and Amortization 61 61
14% 14%
7%
EBIT (Operating Income) EBIT -89 -89
39% 39%
-11%
Net Profit -127 -127
52% 52%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Myriad Genetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Myriad Genetics, Inc. Stock News

Positive
Schaeffers Research
20 days ago
Medical equipment stock Myriad Genetics Inc (NASDAQ:MYGN) was last seen up 9.8% at $11.25, after an upgrade from Piper Sandler to "overweight" from "neutral," with a price-target hike to $12.50 from $11.50.
Neutral
Seeking Alpha
about one month ago
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q4 2024 Results Conference Call February 24, 2025 4:30 PM ET Company Participants Matt Scalo - Senior Vice President of Investor Relations Paul Diaz - President and Chief Executive Officer Sam Raha - Chief Operating Officer Mark Verratti - Chief Commercial Officer Scott Leffler - Chief Financial Officer Conference Call Participants Madeline Mollman - Wolfe R...
Neutral
GlobeNewsWire
about one month ago
Highlights Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing. Fourth quarter GAAP gross margin of 71.7%, increased 300 basis points year-over-year, benefiting from improving revenue per test trends and greater laboratory efficiencies.
More Myriad Genetics, Inc. News

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Paul Diaz
Employees 2,700
Founded 1991
Website www.myriad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today